Global Osteoarthritis Pipeline Study, H1 2020 - Therapeutics, Developments, Products, Drugs, Players
DUBLIN, April 27, 2020 /PRNewswire/ -- The "Osteoarthritis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This pipeline guide provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 7, 22, 22, 1, 47 and 12 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 6 and 7 molecules, respectively.
Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
-- The pipeline guide provides a snapshot of the global therapeutic
landscape of Osteoarthritis (Musculoskeletal Disorders).
-- The pipeline guide reviews pipeline therapeutics for Osteoarthritis
(Musculoskeletal Disorders) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-- The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-- The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing and
collaboration details, R&D brief, MoA & other developmental activities.
-- The pipeline guide reviews key companies involved in Osteoarthritis
(Musculoskeletal Disorders) therapeutics and enlists all their major and
minor projects.
-- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
-- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-- The pipeline guide reviews latest news related to pipeline therapeutics
for Osteoarthritis (Musculoskeletal Disorders).
Reasons to Buy
-- Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-- Recognize emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage.
-- Find and recognize significant and varied types of therapeutics under
development for Osteoarthritis (Musculoskeletal Disorders).
-- Classify potential new clients or partners in the target demographic.
-- Develop tactical initiatives by understanding the focus areas of leading
companies.
-- Plan mergers and acquisitions meritoriously by identifying key players
and it's most promising pipeline therapeutics.
-- Formulate corrective measures for pipeline projects by understanding
Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of
Indication therapeutics.
-- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-- Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered
1. Introduction
2. Overview
3. Therapeutics Development
4. Therapeutics Assessment
5. Companies Involved in Therapeutics Development
6. Drug Profiles
7. Dormant Projects
8. Discontinued Products
9. Product Development Milestones
10. Appendix
Companies Mentioned
-- 4P-Pharma SAS
-- Abiogen Pharma SpA
-- Ablynx NV
-- Aclaris Therapeutics Inc
-- Akaal Pharma Pty Ltd
-- AKL Research and Development Ltd
-- Algomedix Inc
-- Amgen Inc
-- Amplicore Inc
-- Amzell BV
-- Arthrogen BV
-- Asta Pharmaceuticals Co Ltd
-- Atlanthera
-- Aurealis Pharma AG
-- Axsome Therapeutics Inc
-- Bioiberica SAU
-- Bioorg3.14 LLC
-- Bone Therapeutics SA
-- BRIM Biotechnology Inc
-- CAR-T (Shanghai) Biotechnology Co Ltd
-- Cellular Biomedicine Group Inc
-- Chondrogenix Ltd
-- Chugai Pharmaceutical Co Ltd
-- Cocoon Biotech, Inc.
-- Corestem Inc
-- Cynata Therapeutics Ltd
-- Cytonics Corp
-- Daewoong Pharmaceutical Co Ltd
-- DNX Biopharmaceuticals Inc
-- Eli Lilly and Co
-- EnhanX Biopharm Inc
-- Ensol Biosciences Inc
-- Eternity Bioscience Inc
-- Evgen Pharma Plc
-- Flexion Therapeutics Inc
-- Galapagos NV
-- GeneFrontier Corp
-- Genequine Biotherapeutics GmbH
-- General Regeneratives Shanghai Ltd
-- Gwoxi Stem Cell Applied Technology Co Ltd
-- Histogen Inc
-- HSRx Group
-- Inception Therapeutics Inc
-- InKemia IUCT Group SA
-- International Stem Cell Corp
-- K-Stemcell Co Ltd
-- Kang Stem Biotech Co Ltd
-- Kolon TissueGene Inc
-- Kukje Pharmaceutical Industry Co Ltd
-- Lateral Pharma Pty Ltd
-- Levolta Pharmaceuticals Inc
-- LG Chem Ltd
-- Link Health Group
-- Lubris Biopharma
-- Luye Pharma Group Ltd
-- Magellan Biologicals Pty Ltd
-- MediPost Co Ltd
-- Medivir AB
-- Merck KGaA
-- Mesoblast Ltd
-- MetrioPharm AG
-- Mor Research Applications Ltd
-- NeuroBo Pharmaceuticals Inc
-- New York R&D Center for Translational Medicine and Therapeutics Inc
-- Nordic Bioscience AS
-- Novartis AG
-- Orbis Biosciences Inc
-- Orbsen Therapeutics Ltd
-- OrthoTrophix Inc
-- Paradigm Biopharmaceuticals Ltd
-- Peptinov SAS
-- Personalized Stem Cells Inc
-- Pfizer Inc
-- Philogen SpA
-- PhytoHealth Corp
-- Plakous Therapeutics Inc
-- Progenitor Therapeutics Ltd
-- ProteoThera Inc
-- Regeneus Ltd
-- Regenosine Inc
-- Regulaxis SAS
-- Ribomic Inc
-- Rottapharm Biotech Srl
-- Samumed LLC
-- Seikagaku Corp
-- Serene LLC
-- SL Bigen Inc
-- Steminent Biotherapeutics Inc
-- Stempeutics Research Pvt Ltd
-- Synerkine Pharma BV
-- Synokem Pharmaceuticals Ltd
-- Taiwan Bio Therapeutics Co Ltd
-- Traverse Biosciences Inc
-- Unicocell Biomed Co Ltd
-- Unity Biotechnology Inc
-- WEX Pharmaceuticals Inc
-- Xalud Therapeutics Inc
-- Xintela AB
-- Yooyoung Pharm Co Ltd
-- Zimmer Biomet Holdings Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5ggj4t
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-osteoarthritis-pipeline-study-h1-2020---therapeutics-developments-products-drugs-players-301047584.html
SOURCE Research and Markets
